BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1110 related articles for article (PubMed ID: 29708786)

  • 21. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-flow haemangiomas versus hypervascular hepatocellular carcinoma showing "pseudo-washout" on gadoxetic acid-enhanced hepatic MRI: value of diffusion-weighted imaging in the differential diagnosis of small lesions.
    Nam SJ; Yu JS; Cho ES; Kim JH; Chung JJ
    Clin Radiol; 2017 Mar; 72(3):247-254. PubMed ID: 27789027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of small (≤3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: A STARD-compliant article.
    Shin SK; Kim YS; Choi SJ; Shim YS; Jung DH; Kwon OS; Choi DJ; Kim JH
    Medicine (Baltimore); 2017 Jul; 96(29):e7278. PubMed ID: 28723741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT.
    Park VY; Choi JY; Chung YE; Kim H; Park MS; Lim JS; Kim KW; Kim MJ
    Liver Int; 2014 Nov; 34(10):1593-602. PubMed ID: 24673802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiation of hypervascular primary hepatic tumors showing hepatobiliary hypointensity on gadoxetic acid-enhanced magnetic resonance imaging.
    Park HJ; Kim YK; Min JH; Lee J; Lee SJ; Lee ES; Ahn S
    Abdom Radiol (NY); 2019 Sep; 44(9):3115-3126. PubMed ID: 31134313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative analysis of contrast-enhanced ultrasonography: differentiating focal nodular hyperplasia from hepatocellular carcinoma.
    Pei XQ; Liu LZ; Xiong YH; Zou RH; Chen MS; Li AH; Cai MY
    Br J Radiol; 2013 Mar; 86(1023):20120536. PubMed ID: 23392189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peri-tumoral hyperintensity on hepatobiliary phase of gadoxetic acid-enhanced MRI in hepatocellular carcinomas: correlation with peri-tumoral hyperplasia and its pathological features.
    Yoneda N; Matsui O; Kitao A; Komori T; Kozaka K; Ikeda H; Yoshida K; Inoue D; Minami T; Koda W; Kobayashi S; Gabata T
    Abdom Radiol (NY); 2018 Aug; 43(8):2103-2112. PubMed ID: 29260280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis.
    Suh CH; Kim KW; Kim GY; Shin YM; Kim PN; Park SH
    Eur Radiol; 2015 Apr; 25(4):950-60. PubMed ID: 25537979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Focal Nodular Hyperplasia and Hepatocellular Adenoma: Accuracy of Gadoxetic Acid-enhanced MR Imaging--A Systematic Review.
    McInnes MD; Hibbert RM; Inácio JR; Schieda N
    Radiology; 2015 Nov; 277(2):413-23. PubMed ID: 26020440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of volumetric contrast-enhanced and diffusion-weighted MRI in differentiating between common primary hypervascular liver tumors.
    Zarghampour M; Fouladi DF; Pandey A; Ghasabeh MA; Pandey P; Varzaneh FN; Khoshpouri P; Shao N; Pan L; Grimm R; Kamel IR
    J Magn Reson Imaging; 2018 Oct; 48(4):1080-1090. PubMed ID: 29630756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocellular carcinoma and focal nodular hyperplasia of the liver: differentiation with CT spectral imaging.
    Yu Y; Lin X; Chen K; Chai W; Hu S; Tang R; Zhang J; Cao L; Yan F
    Eur Radiol; 2013 Jun; 23(6):1660-8. PubMed ID: 23306709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging features of hepatic sarcomatous carcinoma on computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
    Gu KW; Kim YK; Min JH; Ha SY; Jeong WK
    Abdom Radiol (NY); 2017 May; 42(5):1424-1433. PubMed ID: 28078380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.
    Auer TA; Walter-Rittel T; Geisel D; Schöning W; Schmelzle M; Müller T; Sinn B; Denecke T; Hamm B; Fehrenbach U
    BMC Med Imaging; 2021 Feb; 21(1):28. PubMed ID: 33588783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parametric imaging with contrast-enhanced ultrasound: usefulness for characterization of dynamic effects of microvascularization for hepatocellular carcinoma and focal nodular hyperplasia.
    Zheng SG; Xu HX; Liu LN; Wang Y; Zhang YF; Guo LH; Liu C; Xu JM; Sun LP; Wu J
    Clin Hemorheol Microcirc; 2013; 55(3):375-89. PubMed ID: 23271200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
    Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
    Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of gadoxetic acid-enhanced and diffusion-weighted MR imaging in evaluation of hepatocellular carcinomas with atypical enhancement pattern on contrast-enhanced multiphasic MDCT in patients with chronic liver disease.
    Kim HS; Kim SH; Kang TW; Song KD; Choi D; Park CK
    Eur J Radiol; 2015 Apr; 84(4):555-62. PubMed ID: 25617950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
    Nakao S; Tanabe M; Okada M; Furukawa M; Iida E; Miyoshi K; Matsunaga N; Ito K
    Jpn J Radiol; 2019 Sep; 37(9):651-659. PubMed ID: 31321619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance.
    Min JH; Kim YK; Sinn DH; Choi SY; Jeong WK; Lee WJ; Ha SY; Ahn S; Kim MJ
    Abdom Radiol (NY); 2018 Sep; 43(9):2309-2320. PubMed ID: 29470629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatocellular carcinoma and focal nodular hyperplasia in patients with Fontan-associated liver disease: characterisation using dynamic gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MRI.
    Shiina Y; Inai K; Sakai R; Tokushige K; Nagao M
    Clin Radiol; 2023 Mar; 78(3):e197-e203. PubMed ID: 36481111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
    Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
    Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.